NEW YORK (GenomeWeb News) – The Institute of Cancer Research, London has granted Oxford Gene Technology a license to develop a panel of diagnostic and prognostic prostate cancer microRNA biomarkers into a new assay, OGT said today.

The license is the result of a three-year collaboration, under which ICR and OGT discovered new microRNA biomarkers with a range of applications for the diagnosis, prognosis, treatment planning, and monitoring of prostate cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: self-assembly of DNA components in solution, and more.

Genetics and Molecular Research retracts two gastric cancer papers for being "substantially equal" to other papers, according to Retraction Watch.

A new analysis indicates that the Ebola virus behind the current West African outbreak is mutating at about the same rate as other Ebola viruses.

With the launch of Scott Kelly into space today, the study of him and his earthbound brother to disentangle the effects of life in space from the effects of genetics kicks off.